Table 1.
Baseline characteristics.
| n=42 (100%) | |
|---|---|
| Age, years (Median) |
66 (28-80) |
| Melanoma subtype n (%) Cutaneous Acral Mucosal Uveal Unknown |
26 (62%) 6 (14%) 4 (10%) 5 (12%) 1 (2%) |
| BRAF V600 Mutation n (%) V600E/K Mutated Non V600 Mutated Wildtype |
13 (31%) 1 (2%) 28 (67%) |
| ECOG PS n (%) 0 1 2 3 |
21 (50%) 12 (29%) 8 (19%) 1 (2%) |
| Serum LDH n (%) Normal range Elevated <X2 UNL Elevated >X2 UNL Unknown |
14 (33%) 19 (45%) 8 (19%) 1 (2%) |
| Metastatic at presentation n (%) Yes No |
7 (17%) 35 (83%) |
| Active CNS metastases n (%) Yes No |
13 (31%) 29 (69%) |
| Liver metastases n (%) Yes No |
17 (40%) 25 (60%) |
| Bone metastases n (%) Yes No |
9 (21%) 33 (79%) |
| Lenvatinib + Anti PD-1 line n (%) 2nd 3rd 4th 5th |
15 (35%) 13 (31%) 7 (17%) 7 (17%) |
| Previous lines of treatment Ipilimumab+Nivolumab combination Single agent anti PD-1 |
37 (88%) 5 (12%) |
PS, performance status; LDH, lactate dehydrogenase; UNL, upper normal limit; CNS, central nervous system.